Orca-Q Shows Promise in High-Risk Hematologic Cancers and BFT Conditioning May Synergize With the Agent
Avelumab Maintenance Improves OS and PFS in Advanced Urothelial Carcinoma, Regardless of Diabetes Status
Obe-Cel Elicits High MRD-Negative Response Rates in R/R B-ALL
Axatilimab Displays Durable Responses in cGVHD Irrespective of Number of Prior Lines of Treatment